Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Eur J Heart Fail ; 5(1): 73-9, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12559218

ABSTRACT

BACKGROUND: Five to 10% of patients with acute myocardial infarction develop cardiogenic shock and the majority of these patients are expected to die within the first few weeks. In this study, we review our recent experience in the management of patients with cardiogenic shock complicating MI and examine the effect of early invasive revascularisation on mortality. METHODS: Thirty-six consecutive patients who developed cardiogenic shock less than 48 h after MI were retrospectively evaluated and divided into two treatment groups. One group received early invasive revascularisation (n=24) and the other group had no early invasive revascularisation, but received similar conventional intensive care medical treatment (n=12). RESULTS: Baseline characteristics and hemodynamic variables were similar in both groups. Apart from invasive revascularisation and the use of intra aortic balloon counterpulsation (IABP), treatment strategies did not differ between the two groups. Thirty-day mortality was 21% in the revascularised group of patients and 58% in the non-revascularised group (P<0.05). CONCLUSIONS: Our data support previous observations suggesting that an aggressive treatment strategy including early invasive revascularisation and IABP is associated with improved short and long-term survival in patients with cardiogenic shock. Since early revascularisation appears safe with a considerable treatment benefit, this approach must be considered in patients with short shock duration early after MI.


Subject(s)
Myocardial Infarction/complications , Myocardial Infarction/therapy , Myocardial Revascularization , Shock, Cardiogenic/complications , Shock, Cardiogenic/therapy , Abciximab , Adult , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Anticoagulants/therapeutic use , Denmark , Female , Follow-Up Studies , Hospital Mortality , Humans , Immunoglobulin Fab Fragments/therapeutic use , Length of Stay , Male , Middle Aged , Postoperative Complications/etiology , Postoperative Complications/mortality , Retrospective Studies , Time , Time Factors , Treatment Outcome
2.
Stroke ; 32(1): 128-32, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11136927

ABSTRACT

BACKGROUND AND PURPOSE: Under normal circumstances, autoregulation maintains cerebral blood flow (CBF) constant within a wide range of mean arterial pressure (MAP). It remains unknown whether patients resuscitated from cardiac arrest have preserved CBF autoregulation. In this study, CBF autoregulation was investigated within the first 24 hours after resuscitation from cardiac arrest. METHODS: Eighteen patients and 6 healthy volunteers had relative changes in CBF determined by transcranial Doppler mean flow velocity (V(mean)) in the middle cerebral artery during a stepwise rise in MAP by use of norepinephrine infusion. V(mean) was plotted against MAP, and a lower limit of autoregulation was identified by double regression analysis based on the least-squares method. RESULTS: In patients, V(mean) increased from a median of 33 (range 19 to 73) to 37 (22 to 100) cm/s (P:<0.001) during a norepinephrine-induced rise in MAP from 78 (46 to 118) to 106 (60 to 149) mm Hg. Eight of 18 patients had impaired CBF autoregulation, and in 5 of the 10 patients with preserved CBF autoregulation, the lower limit of autoregulation could be identified. The lower limit of CBF autoregulation was 76 mm Hg (41 to 105 mm Hg) in the volunteers and 114 mm Hg (80 to 120 mm Hg) in the 5 patients with preserved autoregulation (P:<0.01). CONCLUSIONS: We conclude that in a majority of patients in the acute phase after cardiac arrest, cerebral autoregulation is either absent or right-shifted. These results indicate that MAP should be kept at a higher level than commonly accepted to secure cerebral perfusion. We recommend, however, that further randomized clinical trials are performed to determine whether sympathomimetic drugs improve neurological outcome.


Subject(s)
Blood Flow Velocity , Cardiopulmonary Resuscitation/adverse effects , Cerebrovascular Circulation , Cerebrovascular Disorders/etiology , Heart Arrest/physiopathology , Homeostasis , Adult , Aged , Aged, 80 and over , Blood Flow Velocity/drug effects , Blood Pressure/drug effects , Cerebrovascular Circulation/drug effects , Cerebrovascular Disorders/diagnosis , Female , Heart Arrest/therapy , Homeostasis/drug effects , Humans , Male , Middle Aged , Middle Cerebral Artery/diagnostic imaging , Middle Cerebral Artery/physiopathology , Norepinephrine , Ultrasonography, Doppler, Transcranial
SELECTION OF CITATIONS
SEARCH DETAIL
...